Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis

Table 3 Cost-effectiveness analysis of breast cancer screening using a single cohort

	0 % discount^a			3 % discount^a
	Mean	95 % CI		Mean	95 % CI
Screened population
Total costs (Million Euros)	213.0	204.7	221.3	161.9	155.9	167.8
Screening mammography costs	12.5	12.458	12.5	12.5	12.5	12.5
Screening diagnosis workup	2.9	2.7	3.1	2.9	2.8	3.1
Clinical cancers diagnosis workup	3.0	2.9	3.2	2.2	2.1	2.3
Treatment costs	194.5	186.3	202.8	144.2	138.3	150.1
QALYs	1,231,858	1,228,748	1,234,968	997,681	995,195	1,000,168
Non-screened population
Total costs (Million Euros)	206.7	197.4	216.0	153.2	146.5	160.0
Screening mammography costs	0.0	0.0	0.0	0.0	0.0	0.0
Screening diagnosis workup	0.0	0.0	0.0	0.0	0.0	0.0
Clinical cancers diagnosis workup	3.9	3.7	4.1	3.1	2.9	3.2
Treatment costs	202.8	193.6	212.1	150.2	143.5	156.9
QALYs	1,229,578	1,226,441	1,232,715	995,803	993,304	998,301
Difference (Screened - Unscreened)
Total costs (Million Euros)	6.3	2.5	10.1	8.6	5.7	202.8
Screening mammography costs	12.5	12.5	12.5	12.5	12.5	12.5
Screening diagnosis workup	2.9	2.7	3.1	2.9	2.8	3.1
Clinical cancers diagnosis workup	−0.9	−1.1	−0.7	−0.9	−1.0	−0.7
Treatment costs	−8.3	−12.1	−4.5	−6.0	−8.9	−3.0
QALYs	2,280	1,986	2,575	1,879	1,650	2,108
ICER	2,778	974	4,582	4,623	2,830	6,416

CI confidence interval, QALY quality-adjusted life years, ICER incremental cost-effectiveness ratio
^aDiscount applied beginning from the end of the evaluated period until death

ISSN: 1471-2407